Hope O'Brien

Dr. Hope O'Brien

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
BCBasit Ali Chaudhry
Basit Ali Chaudhry
Christopher Louis RobinsonChristopher Louis Robinson
Christopher Louis Robinson
ECEdoardo Caronna
Edoardo Caronna
FDFreda Dodd-Glover
Freda Dodd-Glover
AVAmrittej Singh Virk
Amrittej Singh Virk
SASait Ashina
Sait Ashina
Temporomandibular disorders (TMDs) are common musculoskeletal chronic orofacial pain conditions involving peripheral and central sensitization within trigeminal nociceptive pathways, manifesting as mechanical allodynia and functional impairment. Botulinum toxin type A (BoNT-A) has been explored as a treatment targeting both muscle hyperactivity and nociceptive modulation. Preclinical and clinical evidence demonstrate that BoNT-A reduces peripheral neurotransmitter release, neurogenic inflammation, and central neuronal excitability, leading to attenuation of mechanical allodynia in TMD models and patients. Clinical trials show modest and variable analgesic effects, with patients displaying sensory sensitization appearing to respond more favorably, though methodological heterogeneity limits definitive conclusions. Safety concerns related to muscle weakening, changes in bone density, and structural changes underscore the need for standardized protocols optimizing dosing and monitoring, in addition to prospective studies. These findings suggest that BoNT-A may serve as an adjunctive, mechanism-based therapy within multimodal TMD management. Future research should focus on standardized sensory phenotyping and trial design to clarify BoNT-A’s role in modulating central sensitization and improving patient outcomes.

1 June 2024 in Neurology Clinical Practice
Verified
Journal Article
Closed access
RGRobert C. Gibler
Robert C. Gibler
MMMaya A. Marzouk
Maya A. Marzouk
JPJames Peugh
James Peugh
BRBrooke L. Reidy
Brooke L. Reidy
MEMichelle M. Ernst
Michelle M. Ernst
SSShalonda K. Slater
Shalonda K. Slater
This cross-sectional observational study retrospectively examined clinical data collected from adolescents and young adults (AYAs) seeking care in a specialty headache clinic. We characterized participants' headache characteristics and psychological functioning and examined the association between self-reported anxiety and depressive symptoms and headache frequency, severity, and disability. During their clinic visit, AYAs (M age = 18.36; range = 14-32, 79.5% female) completed an intake questionnaire and reported about their headache characteristics (i.e., frequency, severity, and duration of symptoms in months), mental health history (i.e., previous diagnosis of an anxiety or depressive disorder), and utilization of emergency department (ED) services for migraine. AYAs also completed psychometrically validated screening tools for anxiety and depressive symptoms (i.e., the GAD-7 and PHQ-9). We computed descriptive statistics and examined associations among scores on psychological measures and headache characteristics, including migraine-related disability. We also tested whether individuals with clinically elevated GAD-7 and PHQ-9 scores had higher levels of disability relative to those with fewer/subclinical levels of anxiety and depressive symptoms. Participants (N = 283) reported more than 19 headache days per month on average, with more than 90% describing their average headache intensity as moderate or severe. Nearly half of AYAs reported severe headache-related disability. Approximately one-quarter of AYAs reported a previous diagnosis anxiety or depressive disorder diagnosis, and more than one-third scored above clinical cutoffs on the PHQ-9 and GAD-7. Higher scores on both psychological screening instruments were associated with greater headache frequency. More than 10% of patients endorsed current suicidal ideation; this was not related to headache-related disability. Participants reported a high degree of ED utilization for headache; these rates were unrelated to endorsement of psychological comorbidities. In this sample of AYAs, headache characteristics were generally unrelated to scores on measures on psychological functioning. However, the observed rates of clinically elevated anxiety/depressive symptoms and suicidality in this sample of AYAs underscore the importance of screening for psychological comorbidities in neurology clinics that serve this age group, irrespective of self-reported disability. Results also emphasize the need to expand access to behavioral health services for AYAs with headache disorders and the importance of incorporating a biopsychosocial perspective to the transition of health care from pediatrics to adult neurology practice.

15 December 2025 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
ABAndrew M. Blumenfeld
Andrew M. Blumenfeld
LCLarry Charleston
Larry Charleston
DKDeena Kuruvilla
Deena Kuruvilla
BSBelinda Savage‐Edwards
Belinda Savage‐Edwards
RLRichard B. Lipton
Richard B. Lipton
Hope O'BrienHope O'Brien
Hope O'Brien
Objective: Examine treatment responses to and safety of onabotulinumtoxinA for the preventive treatment of chronic migraine ( CM ) among diverse racial groups. Background: Evidence suggests there are differences in headache treatment patterns, symptom profiles, and burden based on race. However, limited data are available describing the response to preventive migraine treatments among these groups. Methods: The C hronic Migraine O nabotulinu M toxinA P rolonged E fficacy open L abel ( COMPEL ) trial was a single‐arm, open‐label, multicenter, prospective study (January 23, 2012–November 16, 2015) that enrolled adults of various races with CM to receive onabotulinumtoxinA 155 U every 12 weeks over 108 weeks. These analyses assessed White, Asian (primarily Republic of Korea residents), and Black/African American subgroups based on self‐report. Pacific Islander/American Indian/Alaska Native and Hispanic/Latinx subgroups were not analyzed separately because of the small sample sizes and potential overlap with predefined racial categories (e.g., Hispanic/Latinx White) for the latter. Analyses of baseline demographics and clinical characteristics, including headache features, across the subgroups were performed. Change from baseline in the number of monthly headache days ( MHDs ), including proportions with ≥50% reduction in MHDs , and change from baseline scores on the 6‐item Headache Impact Test ( HIT ‐6), Migraine Disability Assessment ( MIDAS ) absenteeism, presenteeism, and total scores, and Migraine‐Specific Quality of Life questionnaire version 2.1 ( MSQ v2.1) Role Function–Restrictive ( RFR ), Emotional Function ( EF ), and Role Function–Preventive ( RFP ) domains were evaluated for each subgroup. Results: Of 716 enrolled participants, 582 (81.3%) were White, 89 (12.4%) were Asian, 41 (5.7%) were Black/African American, and 4 (0.6%) were Pacific Islander/American Indian/Alaska Native. Withdrawal from the study occurred for 50.5% of the White subgroup, 32.6% of the Asian subgroup, and 48.8% of the Black/African American subgroup. The most common reasons for study discontinuation were participant withdrawal of granted consent (12.8%) and lost to follow‐up (11.5%). After treatment with onabotulinumtoxinA 155 U every 12 weeks, all subgroups demonstrated significant reductions from baseline in MHDs at all time points to week 108 (all p < 0.001) and 60.3%–73.3% experienced ≥50% reduction from baseline in MHDs at week 108. Each analyzed subgroup demonstrated significant reductions from baseline to week 108 in HIT ‐6 total (all p < 0.001), MIDAS total (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.0062), MIDAS absenteeism (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.002), MIDAS presenteeism (all p < 0.001), MSQ v2.1 RFR (all p < 0.001), MSQ v2.1 EF (White, p < 0.001; Asian, p < 0.001; Black/African American, p = 0.009), and MSQ v2.1 RFP (all p < 0.001) scores. Results in the total population were similar to those in the subgroups. Treatment‐related adverse events were consistent with the known safety profile of onabotulinumtoxinA . Conclusions: OnabotulinumtoxinA safely reduced MHD frequency and patient‐reported disability and improved quality of life as a preventive treatment of CM among diverse subgroups, with results directionally consistent among groups. Trial Registration: COMPEL, ClinicalTrials.gov identifier: NCT01516892.

10 December 2025 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
TSTodd J. Schwedt
Todd J. Schwedt
ASAmaal J. Starling
Amaal J. Starling
JAJessica Ailani
Jessica Ailani
AHAndrew D. Hershey
Andrew D. Hershey
Hope O'BrienHope O'Brien
Hope O'Brien
RLRichard B. Lipton
Richard B. Lipton

6 February 2026 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
LCLarry Charleston
Larry Charleston
CACynthia E. Armand
Cynthia E. Armand
TMTeshamae Monteith
Teshamae Monteith
Hope O'BrienHope O'Brien
Hope O'Brien
CAChandra C. Abbott
Chandra C. Abbott
TFTerence Fullerton
Terence Fullerton
Objective: This post hoc subgroup analysis was conducted using pooled data from three US‐based clinical trials to compare efficacy and safety of rimegepant 75 mg versus placebo in acute migraine in adults who are Black or African American. Background: Migraine, characterized by recurring moderate‐to‐severe unilateral head pain, affects approximately 13% of the population and in the United States affects Black or African American and White populations at similar rates. Despite this, there is stark underrepresentation of Black or African American patients in clinical trials. Rimegepant, an oral small molecule calcitonin gene‐related peptide receptor blocker or antagonist, is approved for acute migraine treatment in the United States; however, treatment has not previously been analyzed in Black or African American adults. Methods: Using pooled data from three US‐based, double‐blind, randomized, placebo‐controlled, multicenter clinical trials (ClinicalTrials.gov, NCT03235479; NCT03237845; NCT03461757), efficacy analyses were conducted on a modified intent‐to‐treat population including all participants who received study medication, had a migraine attack of moderate or severe pain intensity at the time of dosing, and provided ≥1 efficacy datapoint after receiving study treatment. Trials were conducted July 2017 to January 2018 (NCT03235479, NCT03237845) or February 2018 to October 2018 (NCT03461757). The coprimary efficacy endpoints of each trial were freedom from pain (score 0 = none on a 4‐point pain scale) and freedom from most bothersome symptom (MBS) at 2 h post dose. Safety was assessed through reported on‐treatment adverse events, defined as events occurring on or after treatment was received. Analyses were performed in the Black or African American population, in the White population, and in the overall pooled study population (including Black or African American, White, Asian, American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, and multiple races). Results: Overall, 3551 treated participants were in the pooled population; 696 (19.6%) were Black or African American; 2700 (76.0%) were White. In the Black or African American population, rimegepant showed improvements versus placebo in the two coprimary endpoints. For pain freedom 2 h post dose, the stratified risk was 24.4% (88/359) for rimegepant and 18.2% (59/323) for placebo in Black or African American participants; risk difference was 6.2% (95% confidence interval [CI]: 0.1, 12.3; p = 0.047). For MBS freedom 2 h post dose, the stratified risk was 43.1% (155/359) for rimegepant and 35.5% (115/323) for placebo in Black or African American participants; risk difference was 7.6% (95% CI: 0.3, 14.9; p = 0.041). The risk difference was similar in White participants: 7.9% (95% CI: 5.2, 10.6; p < 0.001) for pain freedom 2 h post dose and 9.9% (95% CI: 6.5, 13.4; p < 0.001) for MBS freedom 2 h post dose. Adverse event rates among Black or African American participants treated with rimegepant were 10.7% (39/365) and 7.9% (26/331) in participants receiving placebo. Conclusion: This pooled analysis showed rimegepant 75 mg was effective and well tolerated for migraine treatment in Black or African American adult participants.

1 June 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
LMLeon S. Moskatel
Leon S. Moskatel
LSLiza Smirnoff
Liza Smirnoff
Hope O'BrienHope O'Brien
Hope O'Brien
HSHayley Striegel
Hayley Striegel
JNJohn Ney
John Ney
JRJennifer Robblee
Jennifer Robblee
Refractory migraine (RM) is associated with substantial disability, yet its clinical and health care utilization patterns remain poorly characterized in large, real-world populations. Understanding how preventive treatment progression relates to health care use and patient characteristics may inform earlier identification and care strategies. We sought to evaluate demographic, clinical, and health care utilization patterns in chronic migraine according to the number of preventive medication trials using a large cross-institutional electronic health record (EHR) database. We conducted a retrospective observational study using the Epic Cosmos Cross-institutional EHR Database from January 1, 2016, to December 31, 2024. Adults with chronic migraine (International Classification of Diseases, Tenth Edition code G43.7) were included. Preventive medication trials were categorized into 5 classes: antihypertensives, antidepressants, antiseizure agents, calcitonin gene-related peptide-targeted therapies, and onabotulinumtoxinA. We evaluated demographics, comorbidities, and health care utilization metrics, including inpatient or outpatient dihydroergotamine (DHE) infusions, emergency department (ED) visits for headache, MRI brain orders, and patient EHR portal recency (MyChart). Marginal changes were defined as the percentage point change in outcomes between medication classes. Chi-squared tests and analysis of variance were used with significance set at p < 0.05. A total of 1,572,698 patients were identified by our search criteria; 21.2% were prescribed no preventive medications and 2.5% were prescribed all 5 classes, meeting the study's definition of RM. Health care utilization increased significantly with each additional medication class. The greatest marginal increases occurred between zero to 1 classes for MyChart access (43-day decrease), 1 to 2 classes for ED visits (+9.2%), and 4 to 5 classes for DHE administration (+6.1%) and MRI brain orders (+4.9%). Patients prescribed more preventive classes were older, a higher percentage female sex, White race, with public insurance, residence in the Northeast United States, and live in less socially vulnerable areas. Comorbidity burden increased progressively, with 94.6% of refractory patients having at least 1 comorbidity, most commonly anxiety (78.1%), depression (71.5%), hypertension (56.0%), and asthma (36.3%). All differences were statistically significant (p < 0.001). Higher health care utilization, greater comorbidity burden, and distinct geographic patterns are observed with increasing numbers of preventive medication trials in chronic migraine. These findings highlight the complexity of RM and underscore the need for earlier identification and more equitable access to comprehensive migraine care.